A comparative study of tranexamic acid and ethamsylate in menorrhagia
Keywords:
Menorrhagia Impact Questionnaire (MIQ), Heavy menstrual bleeding, Antifibrinolytic, Dysfunctional uterine bleedingAbstract
Background: Menorrhagia interferes with the woman’s physical, social, emotional, and/or material quality of life. Antifibrinolytic drugs are effective in decreasing excessive menstrual bleeding. The objective of this study was to compare the effects of tranexamic acid and ethamsylate on quality of life in women with menorrhagia.
Methods: The 50 women with menorrhagia were randomised to receive either tranexamic acid or ethamsylate. Twenty five patients were allocated to receive tranexamic acid 500 mg six hourly, and 25 patients to receive ethamsylate 500 mg six hourly. Among the parameters measured by the MIQ were impairment in social activities, work performance, physical activities, productivity, hygienic condition, psychological condition. Health-related quality-of-life question scores (MIQ scores) at baseline and after treatment were calculated as mean for tranexamic acid group and ethamsylate group.
Results: Tranexamic acid and ethamsylate treatment groups showed mean improvement in MIQ scores compared to baseline. However, the total mean score was higher in tranexamic acid group compared to ethamsylate group after three treatment cycles (21 Vs 17).
Conclusions: Use of tranexamic acid and ethamsylate improved health-related quality of life in patients with menorrhagia. Tranexamic acid showed better improvement in health-related quality of life compared to ethamsylate in patients with menorrhagia.
References
Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss: a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320-51.
Wyatt KM, Dimmock PW, Walker TJ, O’Brien PM. Determination of total menstrual blood loss. Fertil Steril 2001;76:125-31.
Shapley M, Jordan K, Croft PR. Why women consult with increased vaginal bleeding: a case-control study. Br J Gen Pract 2002;52:108-13.
Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007;10:183-94.
Shankar M, Chi C, Kadir RA. Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 2008;14:15-20.
Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract 1994;11:394-401.
Hurskainen R, Grenman S, Komi I, Kujansuu E, Luoto R, Orrainen M, et al. Diagnosis and treatment of menorrhagia. Acta Obstet Gynecol Scand 2007;86:749-57.
Smith SK, Abel MH, Kelly RW, Baird DT Prostaglandins and dysfunctional uterine bleeding. Research and Clinical Forums 1983;5:39-43.
Sheppard BL. The pathology of dysfunctional uterine bleeding. Clin Obstet Gynecol 1984;11:227-38.
Nilsson L, Rybo G. Treatment of menorrhagia with an Antifibrinolytic agent, tranexamic acid. Acta Obstet Gynecol Scand 1967;46:572-80.
Chamberlain G, Freeman R, Price F, Kennedy A, Green D, Eve L. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991;98: 707-10.
Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol. 2011;205(4):319.e1-7.
Lukes AS, Moore KA, Muse KN. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstet Gynecol. 2010;116(4):865-875.
Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001;99:238-43.
Kouides PA, Byams VR, Philipp CS, Stein SF, Heit JA, Lukes AS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal Desmopressin and oral tranexamic acid. Br J Haematol 2009;145:212-20.
Srinil S, Jaisamrarn U. Treatment of idiopathic menorrhagia with tranexamic acid. J Med Assoc Thai. 2005 Oct;88 Suppl 2:S1-6.
Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003;63:1417-33.
Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001;86:714-5.
Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993;70:238-40.
